IMR Press / FBL / Volume 14 / Issue 13 / DOI: 10.2741/3589

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases?
Show Less
1 Rangueil Institute of Molecular Medicine, I2 MR, U858 Inserm, IFR31, Toulouse, France
2 Inserm U558, Toulouse, France

Academic Editors: Catherine Kargar, Frederic De Ceuninck, Frederic De Ceuninck

Front. Biosci. (Landmark Ed) 2009, 14(13), 5107–5117; https://doi.org/10.2741/3589
Published: 1 June 2009
(This article belongs to the Special Issue New therapeutic approaches for type 2 diabetes)
Abstract

In humans, the intestinal microflora is inherited from our parents and from the environment. It has established an ecological mutualism with the host, allowing each organism to benefit from the symbiotic relationship. Based on recent evidence, some molecular mechanisms for the role of intestinal microflora on the control of energy metabolism have been proposed. During metabolic diseases such as obesity and diabetes, it has been proposed that an imbalance between the two dominant groups of beneficial bacteria, the Bacteroidetes and the Firmicutes, generates signals controlling the expression of genes by the epithelial intestinal cells. Genes involved in lipid metabolism such as the Fast Induced Adipocyte Factor have been considered as putative targets. In addition, bacterial extracts such as the lipopolysaccharides control the tone of the innate immune system thus regulating the general inflammatory status, insulin resistance, and adipose tissue plasticity. Therefore, strategies aimed at controlling the ecological mutualism between intestinal microflora and the host should lead to a new era of therapeutic and health benefits.

Share
Back to top